Table 2. Clinical characteristics of patients assessed for CCNE1 expression.
| Characteristic | Frequency (%) |
|---|---|
| Number of patients | 57 (100%) |
| Age, yearsa Median (IQR) |
56.6 (51.8–63.3) |
| Stage | |
| I–II | 9 (16.7) |
| III–IV | 45 (83.3) |
| Tumour histology | |
| High-grade serous | 50 (92.6) |
| Others | 4 (7.4) |
| Family history of ovarian or breast cancer | |
| No | 32 (59.3) |
| Yes | 22 (40.7) |
| Residual disease after primary surgery | |
| ≤10 mm | 34 (70.8) |
| >10 mm | 14 (29.2) |
| PFI before bevacizumab – Median (IQR) | 10.5 (7.4–14.0) |
| 6–12 months | 34 (64.2) |
| ≥12 months | 19 (33.3) |
| CT regimen | |
| Platinum + taxane | 19 (33.3) |
| Platinum + gemcitabine | 34 (59.6) |
| Platinum + liposomal doxorubicin | 3 (5.3) |
| Monotherapy | 1 (1.8) |
| Number of previous treatment lines | |
| 1 | 30 (54.5) |
| 2 | 20 (36.4) |
| 3 | 3 (5.5) |
| 4 | 2 (3.6) |
| Surgery | |
| Primary cytoreduction | 34 (60.7) |
| Interval cytoreduction | 22 (39.3) |
| SCS | |
| Yes | 22 (38.6) |
| No | 35 (61.4) |
| CCNE1 overexpression | |
| Yes | 26 (45.6) |
| No | 31 (54.4) |
| CICE-score | |
| 0 | 15 (26.3) |
| 1 | 16 (28.1) |
| 2 | 10 (17.5) |
| 4 | 11 (19.3) |
| 6 | 5 (8.8) |
a
Continuous variables are described as median and interquartile range
IQR, Interquartile range; PFI, Platinum-free interval